Current therapeutic strategies for immune disorders: biologics, small-molecule inhibition, cell therapy, and gene editing are focused on, with concerns about safety, cost, and accessibility thresholds.
Autoinflammatory disorders arise from dysregulated innate immunity, most commonly involving inflammasome activation and excessive interleukin-1 (IL-1) signaling. Although rare, these conditions are increasingly recognized across age groups as genetic testing expands and phenotypic classification improves.
Therapeutic...
A. Diamantopoulos· Journal of Human Immunity· 0 citations
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR)...
Mateusz Miluski, D. Szydłowska, Mikołaj Jońca et al.· International Journal of Inn...· 0 citations
Cellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD and robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.
F. Suárez-Trujillo, Theodore S. Steiner, J. P. Gisbert et al.· Frontiers in Immunology· 0 citations
In parallel, CAR regulatory T cells (CAR Tregs) may offer a complementary approach for IBD therapy by redirecting suppressive immune function in the inflamed intestine and provide a mechanistically attractive strategy to modulate T helper–type 17-driven mucosal inflammation in CD.
This review comprehensively outlines the progress of Treg-based therapeutics, spanning from fundamental biological research to translational applications in autoimmune diseases, and describes the developmental characteristics, suppressive machinery, and heterogeneity of Tregs.
Jingchang Li, Jia Pang, Peipei Wu et al.· Frontiers in Immunology· 0 citations
This review provides a comprehensive overview of the repertoire of therapeutic biologics, their mechanisms of action, pivotal clinical trials, and clinical applications, and delineates strategies to optimize their application in the management of autoimmune and inflammatory diseases.
K. Narayanan· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.